Ann: Zelira Meets Primary Endpoints for Insomnia Trial, page-18

On the hop here … but looks pretty good to me.

The key to success was dealing with a possible placebo effect which the design took care of with a long monitoring period before participants entered the trial. Plus keeping the attrition rate very low – which they did – with only one subject lost.

The effect size (about 5-6 points) is exactly what you would hope for – not just for statistical significance but also for clinical significance.

Of-course you would want to see supporting evidence coming out from the secondaries … but so far so good.

The good design here has translated good outcomes … as I had earlier argued (hoped) it might.

So well done ZLD … will read the journal paper with interest which will provide more details to look under the hood … but overall can’t fault anything from this announcement.